g6pc3 Antibody

What are the primary applications for G6PC3 antibodies in research?

G6PC3 antibodies are primarily used for Western Blot (WB) and Immunofluorescence (IF) applications. These techniques allow visualization and quantification of G6PC3 protein in various experimental systems. Western Blot is particularly useful for detecting the 38.7 kDa G6PC3 protein in tissue or cell lysates, while immunofluorescence helps determine subcellular localization in the endoplasmic reticulum . For comprehensive studies, consider combining these techniques with ELISA, which is offered by some antibody suppliers, to quantitatively assess G6PC3 expression levels across different experimental conditions.

How do I select the appropriate G6PC3 antibody for my specific research model?

Selection should be based on:

• Species reactivity: Verify that the antibody recognizes G6PC3 in your research model. G6PC3 orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken species . Ensure cross-reactivity is validated for your specific model organism.

• Epitope region: Consider whether you need an antibody targeting the C-terminal, N-terminal, or middle region of the protein. This is particularly important if studying truncated forms or specific domains of G6PC3.

• Validation data: Prioritize antibodies with published validation data in applications similar to your planned experiments. Review cited literature and provided datasheet information to assess antibody performance.

• Clonality: Polyclonal antibodies offer broader epitope recognition, while monoclonal antibodies provide greater specificity for a single epitope. Your choice depends on experimental needs for sensitivity versus specificity.

What controls should I include when using G6PC3 antibodies in immunoblotting?

For rigorous experimental design, include:

• Positive control: Lysate from tissues with known G6PC3 expression (G6PC3 is ubiquitously expressed across many tissue types)

• Negative control: Consider using:

  • Lysate from G6PC3 knockout models if available

  • Immunodepleted samples

  • Secondary antibody-only controls to assess non-specific binding

• Loading control: Use housekeeping proteins like GAPDH, β-actin, or α-tubulin to normalize G6PC3 protein expression

• Molecular weight marker: Confirm the detected band appears at the expected 38.7 kDa size for human G6PC3

How can I optimize detection of G6PC3 in neutrophils given its role in neutropenia?

Detecting G6PC3 in neutrophils requires special considerations:

• Rapid sample processing: Neutrophils have short half-lives and degrade quickly; process samples immediately after collection

• Protease inhibition: Use comprehensive protease inhibitor cocktails during cell lysis to prevent degradation

• Subcellular fractionation: Enrich for ER membranes where G6PC3 localizes

• Fixation optimization: For immunofluorescence, test different fixation methods as G6PC3 epitopes may be sensitive to overfixation

• Neutrophil isolation: Use density gradient separation techniques that maintain cell viability and minimize activation

When studying G6PC3 deficiency models, consider that neutrophil counts may be significantly reduced, requiring pooling of samples or adjustment of experimental design to account for limited cell numbers .

How do alterations in G6PC3 function affect metabolic assays in immune cells?

When investigating metabolic impacts of G6PC3 alterations:

• Glycolytic stress tests: Measure extracellular acidification rate (ECAR) to assess glycolytic capacity. Research shows G6PC3-deficient monocytes and neutrophils have reduced glycolytic reserve under metabolic stress conditions

• Mitochondrial function: Measure oxygen consumption rate (OCR) to evaluate oxidative phosphorylation. G6PC3-deficient neutrophils show reduced OXPHOS at baseline, while monocytes may maintain normal OXPHOS even with G6PC3 deficiency

• LPS stimulation: Include LPS challenges in metabolic assays as G6PC3-deficient cells demonstrate impaired metabolic reprogramming in response to inflammatory stimuli

• Energy status assessment: Measure ATP/AMP ratios to determine cellular energy status, as G6PC3 deficiency may lead to energy deprivation similar to other hypoglycolytic conditions

Use these metabolic parameters alongside G6PC3 immunodetection to correlate protein expression with functional outcomes.

What approaches can best characterize the relationship between G6PC3 deficiency and inflammatory responses?

To investigate inflammation in G6PC3 deficiency:

• Cytokine profiling: Measure pro-inflammatory cytokines, particularly:

  • IL-1β and IL-18 (NLRP3 inflammasome dependent)

  • IL-6 and TNF (often elevated in G6PC3 deficiency)

• NLRP3 inflammasome assessment:

  • Measure ASC speck formation using flow cytometry or imaging

  • Quantify caspase-1 activation

  • Assess pyroptosis markers, as G6PC3-deficient cells show increased pyroptosis

• Metabolic inhibitor studies: Use glycolysis inhibitors to determine whether metabolic dysfunction directly drives inflammatory phenotypes

• Rescue experiments: Test whether restoring glycolytic function can normalize inflammatory responses in G6PC3-deficient cells

These approaches can help distinguish direct effects of G6PC3 deficiency from secondary inflammatory consequences.

How do I design experiments to investigate specific G6PC3 mutations like c.130 C>T?

When studying specific mutations:

• Antibody epitope selection: Choose antibodies whose epitopes do not overlap with the mutation site to ensure recognition of the mutant protein

• Functional assays: The c.130 C>T mutation causes almost total loss of phosphohydrolase activity of G6Pase-β despite potentially milder clinical phenotypes

• Neutrophil oxidative burst: Include this assay as c.130 C>T mutation may not significantly affect neutrophil oxidative burst despite impacting other functions

• LPS-induced glycolysis: Measure glycolytic response to LPS, as cells with c.130 C>T mutation show impaired glycolytic adaptation under stress

• Inflammasome activation: Examine NLRP3 inflammasome activity, as c.130 C>T mutation is associated with increased IL-1β and IL-18 production and ASC speck release

Design experiments that can distinguish between consequences of complete G6PC3 deficiency versus hypomorphic mutations with partial function.

What methodological approaches help differentiate between neutropenia and autoinflammatory phenotypes in G6PC3 deficiency?

To investigate this clinical spectrum:

• Comprehensive immune phenotyping:

  • Absolute neutrophil counts (flow cytometry)

  • Neutrophil function assays (chemotaxis, phagocytosis, ROS production)

  • Pro-inflammatory cytokine production (IL-1β, IL-18, IL-6, TNF)

• Metabolic characterization:

  • Glycolytic reserve measurement using Seahorse technology

  • Energy balance assessment

  • Redox state evaluation

• Cell death pathway analysis:

  • Apoptosis markers (Annexin V/PI staining)

  • Pyroptosis markers (ASC speck formation)

  • Comparison between different immune cell types

• Gene expression profiling:

  • Compare expression signatures between neutropenic and autoinflammatory phenotypes

  • Identify differentially expressed inflammatory pathway components

Use G6PC3 antibodies to quantify protein expression levels and correlate with these functional readouts to establish genotype-phenotype correlations.

What are the common pitfalls when detecting G6PC3 in tissue samples and how can they be addressed?

Common challenges include:

• Membrane protein isolation: G6PC3 localizes to the ER membrane , requiring optimized lysis buffers:

  • Use detergents appropriate for membrane proteins (e.g., CHAPS, Triton X-100)

  • Avoid excessive sonication that may disrupt epitopes

  • Consider membrane fractionation protocols to enrich for ER membranes

• Cross-reactivity: G6PC3 belongs to a family including G6PC1 and G6PC2 :

  • Verify antibody specificity through knockout controls

  • Use peptide competition assays to confirm specificity

  • Compare staining patterns with published localization data

• Low expression levels:

  • Implement signal amplification methods like tyramide signal amplification

  • Optimize protein loading for Western blots

  • Use high-sensitivity detection systems

• Tissue-specific considerations:

  • Adjust fixation protocols based on tissue type

  • Consider antigen retrieval optimization

  • Use fresh samples when possible to maintain protein integrity

How should I interpret conflicting results between G6PC3 protein expression and functional assays?

When facing discrepancies:

• Protein activity vs. abundance: G6PC3 mutations may affect enzymatic function without altering protein levels :

  • Complement antibody detection with functional glucose-6-phosphatase activity assays

  • Consider post-translational modifications that affect function but not detection

• Subcellular localization changes:

  • Use subcellular fractionation and immunofluorescence to determine if protein localization is altered

  • Compare ER marker co-localization between normal and abnormal samples

• Isoform consideration:

  • Verify which isoforms your antibody detects

  • Use multiple antibodies targeting different epitopes

  • Consider RNA analysis to determine which transcripts are expressed

• Technical validation:

  • Test multiple antibody lots and suppliers

  • Include appropriate positive and negative controls

  • Use complementary detection methods (e.g., mass spectrometry)

How can G6PC3 antibodies be utilized in investigating the link between metabolism and inflammation?

Advanced research approaches include:

• Immunometabolism studies:

  • Co-stain for G6PC3 and glycolytic enzymes to visualize metabolic machinery

  • Correlate G6PC3 expression with metabolic parameters (glycolytic reserve, OXPHOS)

  • Track changes in G6PC3 expression during metabolic reprogramming of immune cells

• Inflammasome activation analysis:

  • Use proximity ligation assays to detect interactions between G6PC3 and inflammasome components

  • Apply G6PC3 antibodies in ChIP-seq to identify potential regulatory relationships

  • Combine with phospho-specific antibodies to track signaling cascades

• Single-cell approaches:

  • Implement G6PC3 antibodies in CyTOF or spectral cytometry panels

  • Correlate G6PC3 expression with inflammatory markers at single-cell resolution

  • Perform spatial transcriptomics alongside protein detection

These approaches can help elucidate the mechanisms by which G6PC3 deficiency leads to both neutropenia and autoinflammatory phenotypes .

What considerations are important when developing in vitro models to study G6PC3 function?

When establishing cellular models:

• Cell type selection:

  • Primary neutrophils have short lifespans but are most relevant

  • Monocytic cell lines offer longer experimental windows

  • Consider iPSC-derived neutrophils for long-term studies

• Genetic manipulation strategies:

  • CRISPR/Cas9 for complete knockout studies

  • Site-directed mutagenesis to introduce specific mutations (e.g., c.130 C>T)

  • Inducible systems to study acute vs. chronic G6PC3 deficiency

• Validation approaches:

  • Confirm G6PC3 deletion/mutation at protein level using antibodies

  • Verify expected metabolic consequences (reduced glycolytic reserve)

  • Assess inflammatory phenotypes (increased pro-inflammatory cytokine production)

• Experimental conditions:

  • Include metabolic stress conditions

  • Test responses to inflammatory triggers like LPS

  • Consider co-culture systems to study cell-cell interactions